News articles about DexCom (NASDAQ:DXCM) have trended somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. DexCom earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the medical device company an impact score of 46.5974631310066 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news headlines that may have effected Accern’s analysis:
DexCom (NASDAQ:DXCM) opened at $57.88 on Tuesday. DexCom has a 52-week low of $42.62 and a 52-week high of $88.80. The company has a current ratio of 5.86, a quick ratio of 5.50 and a debt-to-equity ratio of 0.84.
A number of analysts recently weighed in on DXCM shares. Barclays restated an “equal weight” rating and set a $60.00 target price (down from $76.00) on shares of DexCom in a research note on Thursday, September 28th. Citigroup lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Leerink Swann reiterated a “buy” rating and issued a $57.00 price target (down from $85.00) on shares of DexCom in a research note on Friday, September 29th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $78.00 price target (down from $87.00) on shares of DexCom in a research note on Wednesday, August 16th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company’s stock. DexCom presently has an average rating of “Buy” and an average target price of $70.69.
In related news, CEO Kevin R. Sayer sold 12,000 shares of DexCom stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $55.00, for a total transaction of $660,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Andrew K. Balo sold 3,244 shares of DexCom stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $72.27, for a total value of $234,443.88. The disclosure for this sale can be found here. In the last quarter, insiders have sold 37,954 shares of company stock valued at $2,266,296. 1.70% of the stock is currently owned by company insiders.
WARNING: This report was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/05/dexcom-dxcm-getting-somewhat-positive-press-coverage-study-finds.html.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.